International challenge to predict the impact of radioxenon releases from medical isotope production on a comprehensive nuclear test ban treaty sampling station. (June 2016)

• Record Type: Journal Article
• Authors: Eslinger, Paul W.; Bowyer, Ted W.; Achim, Pascal; Chai, Tianfeng; Deconninck, Benoit; Freeman, Katie; Generoso, Sylvia; Hayes, Philip; Heidmann, Verena; Hoffman, Ian; Kijima, Yuichi; Krysta, Monika; Malo, Alain; Maurer, Christian; Ngan, Fantine; Robins, Peter; Ross, J. Ole; Saunier, Olivier; Schlosser, Clemens; Schöppner, Michael; Schrom, Brian T.; Seibert, Petra; Stein, Ariel F.; Ungar, Kurt; Yi, Jing
• Is Part Of: Journal of environmental radioactivity. Volume 157(2016:Jul.)
• Page Start: 41
• Page End: 51
• Publication Date: 2016-06
• Subjects: Medical isotope production -- 133Xe -- Source-term estimation -- Atmospheric modeling -- CTBTO; Radioactivity -- Periodicals; Radiation, Background -- Periodicals; Radioecology -- Periodicals; Radioactive pollution -- Periodicals; Environmental Pollutants -- Periodicals; Radioactive Pollutants -- Periodicals; Radioactivity -- Periodicals; Radioécologie -- Périodiques; Pollution radioactive -- Périodiques; Fond de rayonnement -- Périodiques; 539.752
• DOI: 10.1016/j.jenvrad.2016.03.001
• Languages: English
• ISSNs: 0265-931X

Abstract

Abstract: The International Monitoring System (IMS) is part of the verification regime for the Comprehensive Nuclear-Test-Ban-Treaty Organization (CTBTO). At entry-into-force, half of the 80 radionuclide stations will be able to measure concentrations of several radioactive xenon isotopes produced in nuclear explosions, and then the full network may be populated with xenon monitoring afterward. An understanding of natural and man-made radionuclide backgrounds can be used in accordance with the provisions of the treaty (such as event screening criteria in Annex 2 to the Protocol of the Treaty) for the effective implementation of the verification regime. Fission-based production of 99 Mo for medical purposes also generates nuisance radioxenon isotopes that are usually vented to the atmosphere. One of the ways to account for the effect emissions from medical isotope production has on radionuclide samples from the IMS is to use stack monitoring data, if they are available, and atmospheric transport modeling. Recently, individuals from seven nations participated in a challenge exercise that used atmospheric transport modeling to predict the time-history of 133 Xe concentration measurements at the IMS radionuclide station in Germany using stack monitoring data from a medical isotope production facility in Belgium. Participants received only stack monitoring data and used the atmospheric transport model and meteorological data of their choice. Some of the models predicted the highest measured concentrations quite well. A model comparison rank and ensemble analysis suggests that combining multiple models may provide more accurate predicted concentrations than any single model. None of the submissions based only on the stack monitoring data predicted the small measured concentrations very well. Modeling of sources by other nuclear facilities with smaller releases than medical isotope production facilities may be important in understanding how to discriminate those releases from releases from a nuclear explosion. Highlights: 133 Xe releases from a medical isotope production facility impacts IMS noble gas samplers. International study to predict airborne radioxenon concentrations at an IMS noble gas sampler. Model ensembles predicted concentrations better than individual models.